HB Wealth Management LLC Purchases 8,406 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

HB Wealth Management LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 46.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,411 shares of the biopharmaceutical company’s stock after buying an additional 8,406 shares during the period. HB Wealth Management LLC’s holdings in Gilead Sciences were worth $2,440,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. nVerses Capital LLC purchased a new position in Gilead Sciences in the 3rd quarter worth approximately $25,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences in the 4th quarter valued at $29,000. Valued Wealth Advisors LLC grew its position in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares during the last quarter. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences in the 2nd quarter valued at $33,000. Finally, Friedenthal Financial bought a new position in shares of Gilead Sciences during the 3rd quarter worth $50,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now owns 138,919 shares in the company, valued at $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares in the company, valued at $7,427,227.92. This represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 456,234 shares of company stock worth $42,130,461. 0.29% of the stock is owned by corporate insiders.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $91.84 on Monday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90. The company has a market cap of $114.46 billion, a price-to-earnings ratio of 1,020.44, a PEG ratio of 1.27 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The business’s 50 day moving average price is $91.75 and its 200 day moving average price is $84.08.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter last year, the business posted $2.29 earnings per share. The firm’s revenue was up 7.0% compared to the same quarter last year. On average, research analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.35%. Gilead Sciences’s payout ratio is 3,422.22%.

Analyst Ratings Changes

GILD has been the topic of a number of recent research reports. UBS Group increased their price target on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Barclays increased their price target on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research note on Thursday, November 7th. Citigroup began coverage on Gilead Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price objective on the stock. Daiwa America raised Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $97.96.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.